RedHill Biopharma (RDHL) Total Debt (2020 - 2022)

RedHill Biopharma (RDHL) has reported Total Debt for 3 consecutive years, with $115.2 million the latest figure, recorded in Q4 2022.

• On a quarterly basis, Total Debt rose 37.79% year-over-year to $115.2 million in Q4 2022; TTM through Dec 2022 was $115.2 million, a 37.79% increase from a year earlier, with the FY2022 full-year figure at $115.2 million, up 37.79% from the prior year.
• Total Debt was $115.2 million for Q4 2022 at RedHill Biopharma, up from $113.9 million in the prior quarter.
• Over five years, Total Debt peaked at $115.2 million in Q4 2022 and troughed at $78.2 million in Q1 2020.
• A 3-year average of $87.7 million and a median of $83.3 million in 2021 frame the typical range for Total Debt.
• Across the five-year window, Total Debt climbed 2.74% in 2021 and jumped 37.79% in 2022, its largest moves.
• Over 3 years, Total Debt stood at $81.4 million in 2020, then gained by 2.74% to $83.6 million in 2021, then soared by 37.79% to $115.2 million in 2022.
• The last three Total Debt figures came in at $115.2 million (Q4 2022), $113.9 million (Q3 2022), and $85.5 million (Q2 2022), per Business Quant data.